Research Shows Imagion Nanoparticles Enable Low-field MRI
Imagion Biosystems Limited is pleased to share news of research published by collaborators from the University of Sydney demonstrating that Imagion’s iron oxide nanoparticles enable
Imagion Biosystems Limited is pleased to share news of research published by collaborators from the University of Sydney demonstrating that Imagion’s iron oxide nanoparticles enable
Imagion Biosystems Limited announces that its Chief Financial Officer, Brian Conn, will be leaving the Company effective 1st August 2020. Brian has served as a
Imagion Biosystems Limited (ASX: IBX) is pleased to announce it has become a member of the Nanosystems Engineering Research Center at Boston University, where researchers
The Annual General Meeting (AGM) of Imagion Biosystems Limited (the Company) will be held virtually on Wednesday, 22 July 2020 at 11.00am (Melbourne time). In
We recently announced plans to conduct our first in-human study for MagSense in Australia later this year. In this Market Herald interview, watch IBX CEO Bob
Imagion Biosystems has made the attached Appendix 3Y announcements in relation to change of Directors interest notice. Read Appendix 3Y — Change in Director’s Interest
You can also register to watch the entire Zoom webcast on-demand by clicking here
Imagion Biosystems Limited advises that the 200,000 Performance Rights issued to Directors of the Company under the Company Long-term Incentive Plan on 14 June 2018,
Imagion Biosystems has released an investor webcast presentation announcement to the market. View the webcast presentation.
Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to announce its plans to conduct
Stay informed about our latest news and developments.
© Imagion Biosystems, Ltd. All Rights Reserved | Privacy Policy | Terms & Conditions | Careers | Corporate Governance